HCC Clinical Studies

Three large RCTs are investigating the use of SIR-Spheres® Y-90 resin microspheres for the treatment of Hepatocellular Carcinoma (HCC).

The SARAH and SIRveNIB studies are comparing the efficacy and safety of SIR-Spheres Y-90 resin microspheres versus sorafenib, while the SORAMIC study compares the treatment of HCC with SIR-Spheres Y-90 resin microspheres followed by sorafenib versus sorafenib alone.

SIR-Spheres Y-90 resin microspheres have been extensively used in the treatment of HCC. Various prospective and retrospective studies have been published on SIR-Spheres Y-90 resin microspheres in first-line or second-line therapy across different disease stages. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of HCC

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage